Cited 91 times in
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승업 | - |
dc.contributor.author | 김은혜 | - |
dc.contributor.author | 박미성 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 이도연 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2014-12-19T17:26:36Z | - |
dc.date.available | 2014-12-19T17:26:36Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/91417 | - |
dc.description.abstract | BACKGROUND: The most informative staging system regarding survival outcomes for treatment-naïve hepatocellular carcinoma (HCC) remains debated. We evaluated prognostic values of Barcelona Clinic Liver Cancer (BCLC) stage compared with other staging systems, and identified discrepancies between treatment options chosen in Korean clinical practice and BCLC guidelines. METHODS: Between 2003 and 2008, 1717 prospectively enrolled patients with treatment-naïve HCC were analysed. Prognostic ability of each staging system was assessed using time-dependent receiver-operating characteristic (ROC) curves. RESULTS: The most common aetiology was hepatitis B virus (1238, 72.1%); 167 (9.8%) patients were classified as BCLC stage 0, 526 (30.6%) as A, 333 (19.4%) as B, 608 (35.4%) as C and 83 (4.8%) as D. Median overall survival was 22.5 months, and 1-, 2-, 3-, 4-, and 5-year survival rates were 62.6, 48.3, 39.9, 34.7, and 29.3% respectively. Of six staging systems, BCLC had the highest area under ROC (AUROC; 0.821) for overall survival, followed by JIS (0.809), Tokyo score (0.771), CLIP (0.746), CUPI (0.701) and GRETCH (0.685) system. In both subgroups stratified according to treatment strategy (curative vs. palliative), BCLC also showed the best AUROCs (curative, 0.708/palliative, 0.807) for overall survival. Regarding discrepancies between treatment options chosen in our cohort and BCLC guidelines, more than half with very early/early-stage HCC underwent transarterial chemoembolization, rather than resection or local ablative therapy; most of those with advanced-stage HCC received intra-arterial chemotherapy-based treatments rather than sorafenib. CONCLUSION: BCLC was the best long-term prognostic model for treatment-naïve HCC in a large-scale Korean cohort. However, treatment modalities did not exactly match BCLC paradigm. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Benzenesulfonates/therapeutic use | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology* | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B/epidemiology | - |
dc.subject.MESH | Hepatitis C/epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms/drug therapy | - |
dc.subject.MESH | Liver Neoplasms/mortality* | - |
dc.subject.MESH | Liver Neoplasms/pathology* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Niacinamide/analogs & derivatives | - |
dc.subject.MESH | Phenylurea Compounds | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Pyridines/therapeutic use | - |
dc.subject.MESH | ROC Curve | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Mi Sung Park | - |
dc.contributor.googleauthor | Eun Hye Kim | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Do Youn Lee | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.1111/j.1478-3231.2012.02811.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01462 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02718 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00827 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J02171 | - |
dc.identifier.eissn | 1478-3231 | - |
dc.identifier.pmid | 22524688 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2012.02811.x/abstract | - |
dc.subject.keyword | Barcelona Clinic Liver Cancer (BCLC) staging | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | prognosis | - |
dc.subject.keyword | survival | - |
dc.subject.keyword | treatment | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Kim, Eun Hye | - |
dc.contributor.alternativeName | Park, Mi Sung | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Lee, Do Yun | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Mi Sung | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Do Yun | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Eun Hye | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.citation.volume | 32 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1120 | - |
dc.citation.endPage | 1127 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, Vol.32(7) : 1120-1127, 2012 | - |
dc.identifier.rimsid | 31266 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.